Teva Pharmaceutical Industries Limited (TEVA) - NYSE
  • Sun, May 8, 5:30 PM
    | Sun, May 8, 5:30 PM | 15 Comments
  • Fri, May 6, 10:58 AM
    • Thinly traded micro cap Cardiome Pharma (CRME +27.5%) is up on an 8x surge in volume, albeit on turnover of only 290K shares, in response to its announcement that it has inked a deal with an affiliate of Allergan (AGN -4.5%) (Actavis, presumably) for the commercialization rights to antibiotic XYDALBA (dalbavancin) in France, the U.K., Germany, Belgium, Nordic countries, certain countries in the Middle East, Canada and unnamed others. XYDALBA was approved in May 2014 in the EU for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs).
    • Under the terms of the deal, Cardiome will pay Allergan a staggered upfront fee of $13M, milestones and royalties. Additional terms are not disclosed.
    • Cardiome intends to launch XYDALBA in its territories this year.
    • Related ticker: (TEVA -6.2%)
    | Fri, May 6, 10:58 AM | 14 Comments
  • Fri, May 6, 2:10 AM
    • Teva Pharmaceutical (NYSE:TEVA) is finalizing as much as $2B in asset sale agreements to win U.S. antitrust clearance for its $40.5B acquisition of Allergan's (NYSE:AGN) generic drug portfolio, according to Reuters.
    • Teva said in March that a regulatory review of the deal by the Federal Trade Commission was taking longer than anticipated, and that it expected the transaction to be completed by June.
    | Fri, May 6, 2:10 AM | 34 Comments
  • Mon, May 2, 7:27 AM
    • April monthly performance was: 0%
    • AUM of $359M
    • 52-week performance vs. the S&P 500 is: 0%
    • No dividends were paid in April
    • Top 10 Holdings as of 12/31/2015: Teva Pharmaceutical Industries Ltd ADR (TEVA): 2.13%, Sky PLC (OTCQX:BSYBF): 1.98%, Gilead Sciences Inc (GILD): 1.8%, Apple Inc (AAPL): 1.78%, Newell Rubbermaid Inc (NWL): 1.54%, Amcor Ltd (OTC:AMCRF): 1.48%, CGI Group Inc Class A (GIB): 1.47%, Avago Technologies Ltd (AVGO): 1.46%, CK Hutchison Holdings Ltd (OTCPK:CKHUF): 1.43%, RELX PLC (OTC:RLXXF): 1.43%
    | Mon, May 2, 7:27 AM | 1 Comment
  • Fri, Apr. 29, 1:27 PM
    • The FDA approves a generic version of AstraZeneca's (AZN -0.6%) cholesterol fighter Crestor (rosuvastatin calcium), from Watson Pharmaceuticals (now part of Teva Pharmaceutical Industries (TEVA -0.7%)).
    • The branded version is AstraZeneca's top seller, having generated over $5B in sales the past four quarters.
    • The U.S. launch will, no doubt, commence promptly.
    | Fri, Apr. 29, 1:27 PM | 2 Comments
  • Fri, Apr. 29, 8:24 AM
    • The FDA approves the use of Teva Pharmaceutical Industries' (NYSE:TEVA) ProAir RespiClick (albuterol sulfate) Inhalation Powder for the treatment or prevention of bronchospasm in children 4 to 11 years old with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.
    • ProAir was approved by the FDA 13 months ago for use in patients at least 12 years old.
    | Fri, Apr. 29, 8:24 AM
  • Wed, Apr. 27, 11:13 AM
    • Privately held Sunovion Pharmaceuticals announces successful results from two Phase 3 clinical trials, GOLDEN-3 and GOLDEN-4, assessing an inhalable mist formulation of SUN-101 (glycopyrrolate) in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD). Both studies (25 mcg and 50 mcg doses) met their primary endpoints of a statistically valid change from baseline to week 12 versus placebo in trough forced expiratory volume in one second (FEV1). Full results will be presented at future medical conferences.
    • SUN-101 is a nebulized (mist) long-acting muscarinic antagonist (LAMA) delivered via an inhalation device called eFlow, developed by the German firm PARI.
    • The company intends to file a New Drug Application (NDA) with the FDA this year. According to the company, SUN-101/eFlow, if approved, will be the first nebulized LAMA available for COPD patients, but AstraZeneca (AZN -0.9%) just received FDA approval of its LAMA/LABA offering, Bevespi Aerosphere.
    • Related tickers: (GSK +1.7%)(MYL -1.5%)(NVS -0.2%)(TEVA -0.2%)(THRX)(AQXP -3.3%)
    • Previously: AstraZeneca up 1.6% as FDA approves COPD treatment (April 25)
    | Wed, Apr. 27, 11:13 AM | 1 Comment
  • Wed, Apr. 6, 7:26 AM
    • Although disheartened that its merger with Pfizer (NYSE:PFE) is dead, Allergan (NYSE:AGN) is bullish on its standalone profile. CEO Brent Saunders says, "While we are disappointed that the Pfizer transaction will no longer mover forward, Allergan is poised to deliver strong, sustainable growth built of a set of powerful attributes. Our pipeline is one of the strongest in the industry, loaded with 70 mid-to-late-stage programs including 14 expected approvals and 16 regulatory submissions in 2016 alone."
    • Based on a preliminary review of the proposed regulations from the U.S. Treasury Department, the company believes they will not have a material impact on its standalone tax rate. Q1 earnings will be reported no later than May 10. During the conference call, management will update investors on its plans to simplify the company's operations after it divests its generics business to (NYSE:TEVA).
    • Allergan will host a brief conference call this morning at 10:00 am ET to discuss its standalone prospects.
    • Pfizer says it will make a decision on splitting the company's innovative and established businesses by the end of the year. It will report Q1 results on May 3. It has agreed to reimburse Allergan $150M for merger-related expenses.
    • PFE is up 1% and AGN is down 1% premarket.
    | Wed, Apr. 6, 7:26 AM | 21 Comments
  • Mon, Apr. 4, 7:31 AM
    • March monthly performance was: +8.07%
    • AUM of $331M
    • 52-week performance vs. the S&P 500 is: -11%
    • No dividends were paid in March
    • Top 10 Holdings as of 12/31/2015: Teva Pharmaceutical Industries Ltd ADR (TEVA): 2.13%, Sky PLC (OTCQX:BSYBF): 1.98%, Gilead Sciences Inc (GILD): 1.8%, Apple Inc (AAPL): 1.78%, Newell Rubbermaid Inc (NWL): 1.54%, Amcor Ltd (OTC:AMCRF): 1.48%, CGI Group Inc Class A (GIB): 1.47%, Avago Technologies Ltd (AVGO): 1.46%, CK Hutchison Holdings Ltd (OTCPK:CKHUF): 1.43%, RELX PLC (OTC:RLXXF): 1.43%
    | Mon, Apr. 4, 7:31 AM
  • Fri, Apr. 1, 10:13 AM
    • Teva Pharmaceutical Industries (TEVA +0.5%) and Takeda Pharmaceutical Company Limited (OTCPK:TKPHF)(OTCPK:TKPYY) establish a venture in Japan with the aim of marketing off-patent (generic) drugs. The Nagoya-based company, called Teva Takeda Yakuhin Ltd., will be led by industry veteran Hiroshi Matsumori.
    • Takeda expects the venture to be both earnings and cash flow accretive this year and thereafter. Teva expects accretion to non-GAAP EPS this year as well.
    • Now read Teva: The Future is Generic 
    | Fri, Apr. 1, 10:13 AM
  • Mon, Mar. 28, 7:37 AM
    • Citing the requirement to demonstrate "clinical superiority" as a condition to granting seven-year market exclusivity in the U.S., the FDA rejects Eagle Pharmaceuticals' request for Orphan Drug-tagged BENDEKA (bendamustine hydrochloride injection), approved in December 2015 for the treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
    • The FDA currently requires sponsors of certain Orphan Drug-tagged therapies to show clinical superiority before granting the exclusivity period, specifically, in those cases where the agency has previously approved another drug with the same active moiety for the same indication. Eagle disagrees with the agency's position and is evaluating its options to challenge the decision. BENDEKA had been designated an Orphan Drug for both indications.
    • Eagle cites the case of Depomed (NASDAQ:DEPO), who successfully overturned the FDA's rejection of its exclusivity request for post-herpetic neuralgia med GRALISE (gabapentin) in September 2014 based on the argument that the requirement of demonstrable clinical superiority violated the Orphan Drug Act. Despite losing the case, the FDA has continued to require it for other Orphan Drug-tagged approvals.
    • Eagle extended an exclusive U.S. license for BENDEKA to Teva Pharmaceutical Industries (NYSE:TEVA) in February 2015.
    • Previously: Teva launches short-time infusion formulation of chemo agent bendamustine (Jan. 28)
    • Previously: FDA clears Eagle's BENDEKA for CLL and NHL (Dec. 8, 2015)
    | Mon, Mar. 28, 7:37 AM
  • Wed, Mar. 23, 9:57 AM
    • The FDA approves Teva Pharmaceutical Industries' (TEVA +0.5%) Cinqair (reslizumab) for the maintenance treatment of adults with severe asthma who have a history of severe asthma attacks despite receiving medications.
    • Cinqair, a humanized monoclonal antibody that binds to interleukin-5, is administered via IV infusion every four weeks. It reduces severe asthma attacks by reducing the levels of blood eosinophils, a type of white blood cell that creates inflammation related to allergies and asthma.
    • Asthma affects more than 22M Americans. There are more than 400K asthma-related hospitalizations each year.
    | Wed, Mar. 23, 9:57 AM | 2 Comments
  • Wed, Mar. 23, 3:09 AM
    • The U.S. Supreme Court today will consider appeals by Christian groups demanding full exemption on religious grounds from a requirement under the Affordable Care Act to provide health insurance covering contraceptives.
    • Arguments on seven related cases will focus on whether nonprofit entities can object to a compromise measure offered by the Obama administration, which allowed groups to comply with the law without actually paying for the required coverage, under the 1993 Religious Freedom Restoration Act.
    • Related tickers: PFE, MRK, JNJ, TEVA, CHD, OTCPK:BAYRY
    | Wed, Mar. 23, 3:09 AM | 22 Comments
  • Tue, Mar. 22, 10:05 AM
    • Teva Pharmaceutical Industries (TEVA -0.5%) launches its generic equivalent to Campral (acamprosate calcium) in the U.S. The drug is used for the maintenance of abstinence from alcohol in patients with alcohol dependence who want to remain abstinent.
    • The U.S. market for the drug is ~$14M.
    | Tue, Mar. 22, 10:05 AM
  • Thu, Mar. 10, 2:20 AM
    • Teva Pharmaceutical (NYSE:TEVA) is expected to win EU antitrust approval today for its $40.5B bid for Allergan's (NYSE:AGN) generics unit after agreeing to sell off some of its products to appease regulators, Reuters reports.
    • How much is being sold? Sources previously told the news agency that global assets worth about $1B would be unloaded to secure the green light.
    • The deal, the largest in Israel's corporate history, would see Teva gain bigger economies of scale, a crucial element in the low-margin generic drugs business.
    | Thu, Mar. 10, 2:20 AM | 2 Comments
  • Wed, Mar. 2, 10:06 AM
    • February monthly performance was: +1.02%
    • AUM of $328M
    • 52-week performance vs. the S&P 500 is: -2%
    • No dividends were paid in February
    • Top 10 Holdings as of 12/31/2015: Teva Pharmaceutical Industries Ltd ADR (TEVA): 2.13%, Sky PLC (OTCQX:BSYBF): 1.98%, Gilead Sciences Inc (GILD): 1.8%, Apple Inc (AAPL): 1.78%, Newell Rubbermaid Inc (NWL): 1.54%, Amcor Ltd (OTC:AMCRF): 1.48%, CGI Group Inc Class A (GIB): 1.47%, Avago Technologies Ltd (AVGO): 1.46%, CK Hutchison Holdings Ltd (OTCPK:CKHUF): 1.43%, RELX PLC (OTC:RLXXF): 1.43%
    | Wed, Mar. 2, 10:06 AM | 2 Comments
Company Description
Teva Pharmaceutical Industries Ltd. engages in the provision of pharmaceutical services. It operates through the following business divisions: Generic, Specialty Medicine, and Over-the-Counter (OTC). The Generic division involves the manufacture and sale of generic products such as tablets,... More
Sector: Healthcare
Industry: Drug Manufacturers - Other
Country: Israel